ten Bosch John Roderick sold $287K of BLLN

ten Bosch John Roderick (See Remarks) sold 2,832 shares of BillionToOne, Inc. (BLLN) at $101.47 ($0.29M total) across 2 trades on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ten Bosch John Roderick
Published Jun 17, 2026, 9:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 9:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Bearish
high confidence
Mentioned
$BLLN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNBearishLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

This provides a fresh, timestamped insider-selling datapoint but lacks any fundamental catalyst.

03

What to watch

Traders may overreact to insider selling; without changes to guidance, trials, or financing, the signal-to-noise is low.

Relevance 3/10Novelty 6/10Timing: Filed 2026-06-17; sale executed 2026-06-15.

Background

The article is an SEC Form 4 insider transaction disclosure for BillionToOne, Inc.

Company-level read

Ticker impact

$BLLNBearishHigh confidence
Context

BillionToOne (BLLN) reported an officer open-market sale: 2,832 shares sold at $101.47 on a 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; any move would be more about broader tape than this Form 4.

Evidence & confidence

The filing is a standard Form 4 with a pre-arranged 10b5-1 plan and no accompanying operational or financial guidance changes.

Market effects

No sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

10b5-1 sales are often mechanical; the disclosure may not signal bearish fundamentals and could be offset by other positive catalysts not mentioned here.

Key entities

  • BillionToOne, Inc.

    Subject of the Form 4 insider transaction; officer sold 2,832 shares at $101.47 on 2026-06-15.

  • ten Bosch John Roderick

    Officer who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.